Hypothalamic and pituitary development: Novel insights into the aetiology

European Journal of Endocrinology

Volumn 157, Issue SUPPL. 1, 2007, Pages

  Kelberman, Daniel ^a   Dattani, Mehul Tulsidas ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; FOLLITROPIN; GROWTH HORMONE; LUTEINIZING HORMONE; THYROTROPIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LHX3; TRANSCRIPTION FACTOR LHX4; TRANSCRIPTION FACTOR PIT 1; TRANSCRIPTION FACTOR PROP1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR SOX3; TRANSCRIPTION FACTOR TBX19; UNCLASSIFIED DRUG;

ANOPHTHALMIA; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; BRAIN DEVELOPMENT; CORPUS CALLOSUM AGENESIS; CORTICOTROPIN DEFICIENCY; CRANIOFACIAL MALFORMATION; EMBRYO DEVELOPMENT; FOREBRAIN; FRAMESHIFT MUTATION; GENE DELETION; GONADOTROPIN DEFICIENCY; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HETEROZYGOSITY; HOLOPROSENCEPHALY; HOMOZYGOSITY; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOPITUITARISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; LEARNING DISORDER; MICROPHTHALMIA; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; OPTIC NERVE HYPOPLASIA; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SEPTOOPTIC DYSPLASIA; X CHROMOSOMAL INHERITANCE; X LINKED MENTAL RETARDATION;

ANIMALS; HUMANS; HYPOPITUITARISM; HYPOTHALAMUS; MUTATION; PITUITARY GLAND; PITUITARY HORMONES; PROSENCEPHALON; TRANSCRIPTION FACTORS;

EID: 34548825691     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0156     Document Type: Article

References (114)

1. Takuma N, Sheng HZ, Furuta Y, Ward JM, Sharma K, Hogan LM, Pfaff SL, Westphal H, Kimura S & Mahon KA. Formation of Rathke's pouch requires dual induction from the diencephalon. Development 1998 125/23 4840.
2. Dasen JS & Rosenfeld MG. Signaling mechanisms in pituitary morphogenesis and cell fate determination. Current Opinion in Cell Biology 1999 11 669-677.
3. Dasen JS & Rosenfeld MG. Signaling and transcriptional mechanisms in pituitary development. Annual Review of Neuroscience 2001 24 327-355.
4. Rizzoti K & Lovell-Badge R. Early development of the pituitary gland: induction and shaping of Rathke's pouch. Reviews in Endocrine and Metabolic Disorders 2005 6 161-172.
5. de Morsier G. Studies in cranio-encephalic dysraphia. I. Agenesia of the olfactory lobe (lateral telencephaloschisis) and of the callous and anterior commissures (median telencephaloschisis); olfacto-genital dysplasia. Schweizer Archiv Für Neurologic und Psychiatrie 1954 74 309-361.
6. Reeves DL. Congenital absence of the septum peflucidum. Bulletin of the Johns Hopkins Hospital 1941 69 61-71.
7. Hoyt WF, Kaplan SL, Grumbach MM & Glaser JS. Septo-optic dysplasia and pituitary dwarfism. Lancet 1970 1 893-894.
8. Arslanian SA, Rothfus WE, Foley TP Jr & Becker DJ. Hormonal, metabolic, and neuroradiologic abnormalities associated with septo-optic dysplasia. Acta Endocrinologica 1984 107 282-288.
9. Stanhope R, Preece MA & Brook CG. Hypoplastic optic nerves and pituitary dysfunction. A spectrum of anatomical and endocrine abnormalities. Archives of Disease in Childhood 1984 59 111-114.
10. Patel L, McNally RJ, Harrison E, Lloyd IC & Clayton PE. Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. Journal of Pediatrics 2006 148 85-88.
11. Morishima A & Aranoff GS. Syndrome of septo-optic-pituitary dysplasia: the clinical spectrum. Brain and Development 1986 8 233-239.
12. McNay DE, Turton JP, Kelberman D, Woods KS, Brauner R, Papadimitriou A, Keller E, Keller A, Hauls N, Krude H, Shalet SM & Dattani MT. HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. Journal of Clinical Endocrinology and Metabolism 2007 92 691-697.
13. Acers TE. Optic nerve hypoplasia: septo-optic-pituitary dysplasia syndrome. Transactions of the American Ophthalmological Society 1981 79 425-457.
14. Izenberg N, Rosenblum M & Parks JS. The endocrine spectrum of septo-optic dysplasia. Clinical Pediatrics 1984 23 632-636.
15. Roessmann U, Velasco ME, Small EJ & Hori A. Ncuropathology of 'septo-optic dysplasia' (de Morsier syndrome) with immunohistochemical studies of the hypothalamus and pituitary gland. Journal of Neuropathology and Experimental Neurology 1987 46 597-608.
16. Zaias B & Becker D. Septo-optic dysplasia: developmental or acquired abnormality? A case report Transactions of the American Neurological Association 1978 103 273-277.
17. Wales JK & Quarrell OW. Evidence for possible Mendelian inheritance of septo-optic dysplasia. Acta Paediatrica 1996 85 391-392.
18. Blethen SL & Weldon VV. Hypopituitarism and septo-optic 'dysplasia' in first cousins. American Journal of Medical Genetics 1985 21 123-129.
19. Benner JD, Preslan MW, Gratz E, Joslyn J, Schwartz M & Kelman S. Septo-optic dysplasia in two siblings. American Journal of Ophthalmology 1990 109 632-637.
20. Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, Cameron F, Hurst J, Woods K, Dunger D, Stanhope R, Forrest S, Robinson IC & Beddington RS. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Human Molecular Genetics 2001 10 39-45.
21. Cohen RN, Cohen LE, Botero D, Yu C, Sagar A, Jurkiewicz M & Radovick S. Enhanced repression by HESX1 as a cause of hypopituitarism and septooptic dysplasia. Journal of Clinical Endocrinology and Metabolism 2003 88 4832-4839.
22. Tajima T, Hattorri T, Nakajima T, Okuhara K, Sato K, Abe S, Nakae J & Fujieda K. Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. Journal of Clinical Endocrinology and Metabolism 2003 88 45-50.
23. Thomas PQ, Johnson BV, Rathjen J & Rathjen PD. Sequence, genomic organization, and expression of the novel homeobox gene Hesx1. Journal of Biological Chemistry 1995 270 3869-3875.
24. Dasen JS, Barbera JP, Herman TS, Connell SO, Olson L, Ju B, Tollkuhn J, Baek SH, Rose DW & Rosenfeld MG. Temporal regulation of a paired-like homeodomain repressor/TLE corepressor complex and a related activator is required for pituitary organogenesis. Genes and Development 2001 15 3193-3207.
25. Brickman JM, Clements M, Tyrell R, McNay D, Woods K, Warner J, Stewart A, Beddington RS & Dattani M. Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Development 2001 128 5189-5199.
26. Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, Toresson H, Fox M, Wales JKH, Hindmarsh PC, Krauss S, Beddington RSP & Robinson ICAF. Mutations in the homeobox gene HESX1/ Hesx1 associated with septo-optic dysplasia in human and mouse. Nature Genetics 1998 19 125-133.
27. Sobrier ML, Netchine I, Heinrichs C, Thibaud N, Vie-Luton MP, Van VG & Amselem S. Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Human Mutation 2005 25 503.
28. Sobrier ML, Maghnie M, Vie-Luton MP, Secco A, di IN, Lorini R & Amselem S. Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. Journal of Clinical Endocrinology and Metabolism 2006 91 4528-4536.
29. Tornqvist K, Ericsson A & Kallen B. Optic nerve hypoplasia: risk factors and epidemiology. Acta Ophthalmologica Scandinavica 2002 80 300-304.
30. Stevanovic M, Lovellbadge R, Collignon J & Goodfellow PN. Sox3 is an X-linked gene-related to Sry. Human Molecular Genetics 1993 2 2013-2018.
31. Pevny LH & Lovell-Badge R. Sox genes find their feet. Current Opinion in Genetics and Development 1997 7 338-344.
32. Kamachi Y, Uchikawa M, Collignon J, Lovell-Badge R & Kondoh H. Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction. Development 1998 125 2521-2532.
33. Pevny L & Placzek M. SOX genes and neural progenitor identity. Current Opinion in Neurobiology 2005 15 7-13.
34. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC & Lovell-Badge R. SOX3 is required during the formation of the hypothalamo-pituitary axis. Nature Genetics 2004 36 247-255.
35. Weiss J, Meeks JJ, Hurley L, Raverot G, Frassetto A & Jameson JL. Sox3 is required for gonadal function, but not sex determination, in males and females. Molecular and Cellular Biology 2003 23 8084-8091.
36. Hamel BC, Smits AP, Otten BJ, van den HB, Ropers HH & Mariman EC. Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings. American Journal of Medical Genetics 1996 64 35-41.
37. Lagerstrom-Fermer M, Sundvall M, Johnsen E, Warne GL, Forrest SM, Zajac JD, Rickards A, Ravine D, Landegren U & Pettersson U. X-linked recessive panhypopituitarism associated with a regional duplication in Xq25-q26. American Journal of Human Genetics 1997 60 910-916.
38. Hol FA, Schepens MT, van Beersum SE, Redolfi E, Affer M, Vezzoni P, Hamel BC, Karnes PS, Mariman EC & Zucchi I. Identification and characterization of an Xq26-q27 duplication in a family with spina bifida and panhypopituitarism suggests the involvement of two distinct genes. Genomics 2000 69 174-181.
39. Solomon NM, Nouri S, Warne GL, Lagerstrom-Fermer M, Forrest SM & Thomas PQ. Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarism. Genomics 2002 79 553-559.
40. Stankiewicz P, Thiele H, Schlicker M, Cseke-Friedrich A, Bartel-Friedrich S, Yatsenko SA, Lupski JR & Hansmann I. Duplication of Xq26.2-q27.1, including SOX3, in a mother and daughter with short stature and dyslalia. American Journal of Medical Genetics. Part A 2005 138A 11-17.
41. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R, Wong J, Chong WK, Al Zyoud M, El Ali M, Otonkoski T, Martinez-Barbera JP, Thomas PQ, Robinson IC, Lovell-Badge R, Woodward KJ & Dattani MT. Over- and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. American Journal of Human Genetics 2005 76 833-849.
42. Laumonnier F, Ronce N, Hamel BCJ, Thomas P, Lespinasse J, Raynaud M, Paringaux C, Van Bokhoven H, Kalscheuer V, Fryns JP, Chelly J, Moraine C & Briault S. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. American Journal of Human Genetics 2002 71 1450-1455.
43. Albrecht AN, Kornak U, Boddrich A, Suring K, Robinson PN, Stiege AC, Lurz R, Stricker S, Wanker EE & Mundlos S. A molecular pathogenesis for transcription factor associated polyalanine tract expansions. Human Molecular Genetics 2004 13 2351-2359.
44. Wood HB & Episkopou V. Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages. Mechanisms of Development 1999 86 197-201.
45. Williamson KA, Hever AM, Rainger J, Rogers RC, Magee A, Fiedler Z, Keng WT, Sharkey FH, McGill N, Hill CJ, Schneider A, Messina M, Turnpenny PD, Fantes JA, van HV & FitzPatrick DR. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Human Molecular Genetics 2006 15 1413-1422.
46. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N & Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes and Development 2003 17 126-140.
47. Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR & Pevny LH. SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes and Development 2006 20 1187-1202.
48. Kelberman D, Rizzoti K, Avilion A, Bitner-Glindzicz M, Cianfarani S, Collins J, Chong WK, Kirk JM, Achermann JC, Ross R, Carmignac D, Lovell-Badge R, Robinson IC & Dattani MT. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. Journal of Clinical Investigation 2006 116 2442-2455.
49. Fantes J, Ragge NK, Lynch SA, Mcgill NI, Collin JRO, Howard-Peebles PN, Hayward C, Vivian AJ, Williamson K, van Heyningen V & FitzPatrick DR. Mutations in SOX2 cause anophthalmia. Nature Genetics 2003 33 461-463.
50. Ragge NK, Lorenz B, Schneider A, Bushby K, de Sanctis L, de Sanctis U, Salt A, Collin JRO, Vivian AJ, Free SL, Thompson P, Williamson KA, Sisodiya SM, van Heyningen V & FitzPatrick DR. SOX2 anophthalmia syndrome. American Journal of Medical Genetics. Part A 2005 135A 1-7.
51. Hagstrom SA, Pauer GJT, Reid J, Simpson E, Crowe S, Maumenee IH & Traboulsi EI. SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies. American Journal of Medical Genetics. Part A 2005 138A 95-98.
52. Zenteno JC, Gascon-Guzman G & Tovilla-Canales JL. Bilateral anophthahnia and brain malformations caused by a 20-bp deletion in the SOX2 gene. Clinical Genetics 2005 68 564-566.
53. Sato N, Kamachi Y, Kondoh H, Shima Y, Morohashi K, Horikawa R & Ogata T. Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. European Journal of Endocrinology 2007 156 167-171.
54. Bach I, Rhodes SJ, Pearse RV, Heinzel T, Gloss B, Scully KM, Sawchenko PE & Rosenfeld MG. P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. PNAS 1995 92 2720-2724.
55. Schmitt S, Biason-Lauber A, Betts D & Schoenle EJ. Genomic structure, chromosomal localization, and expression pattern of the human LIM-Homeobox3 (LHX 3) gene. Biochemical and Biophysical Research Communications 2000 274 49-56.
56. Zhadanov AB, Bertuzzi S, Taira M, Dawid IB & Westphal H. Expression pattern of the murine Lim class homeobox gene Lhx3 in subsets of neural and neuroendocrine tissues. Developmental Dynamics 1995 202 354-364.
57. Sheng HZ, Zhadanov AB, Mosinger B, Fujii T, Bertuzzi S, Grinberg A, Lee EJ, Huang SP, Mahon KA & Westphal H. Specification of pituitary cell lineages by the LIM homeobox gene Lhx3. Science 1996 272 1004-1007.
58. Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA & Westphal H. Pituitary organogenesis controlled by LIM-homeobox genes. Developmental Biology 1997 186 B132.
59. Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, Duriez B, Cacheux V, von Moers A, Goossens M, Gruters A & Amselem S. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nature Genetics 2000 25 182-186.
60. Sloop KW, Parker GE, Hanna KR, Wright HA & Rhodes SJ. LHX3 transcription factor mutations associated with combined pituitary hormone deficiency impair the activation of pituitary target genes. Gene 2001 265 61-69.
61. Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, Ten S & Rhodes SJ. A novel LHX3 mutation presenting as combined pituitary hormonal deficiency. Journal of Clinical Endocrinology and Metabolism 2006 91 747-753.
62. Sobrier ML, Attie-Bitach T, Netchine I, Encha-Razavi F, Vekemans M & Amselem S. Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development. Gene Expression Patterns 2004 5 279-284.
63. Pfaeffic RW, Savage JJ, Hunter CS, Palme C, Ahlmann M, Kumar P, Bellone J, Schoenau E, Korsch E, Bramswig JH, Stobbe HM, Blum WF & Rhodes SJ. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. Journal of Clinical Endocrinology and Metabolism 2007 92 1909-1919.
64. Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA & Westphal H. Multistep control of pituitary organogenesis. Science 1997 278 1809-1812.
65. Machinis K, Pantel J, Netchine I, Leger J, Camand OJA, Sobrier ML, Dastot-Le Moal F, Duquesnoy P, Abitbol M, Czernichow P & Amselem S. Syndromic short stature in patients with a germline mutation in the LIM homeohox LHX4. American Journal of Human Genetics 2001 69 961-968.
66. Lamolet B, Pulichino A, Lamonerie T, Gauthier Y, Brue T, Enjalbert A & Drouin J. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001 104 849-859.
67. Liu J, Lin C, Gleiberman A, Ohgi KA, Herman T, Huang HP, Tsai MJ & Rosenfeld MG. Tbx19, a tissue-selective regulator of POMC gene expression. PNAS 2001 98 8674-8679.
68. Pulichino AM, Vallette-Kasic S, Tsai JR, Couture C, Gauthier Y & Drouin J. Tpit determines alternate fates during pituitary cell differentiation. Genes and Development 2003 17 738-747.
69. Pulichino AM, Vallette-Kasic S, Couture C, Gauthier Y, Brue T, David M, Malpuech G, Deal C, Van Vliet G, De Vroede M, Riepe FG, Partsch CJ, Sippell WG, Berberoglu M, Atasay B & Drouin J. Human and mouse TPIT gene mutations cause early onset pituitary ACTH deficiency. Genes and Development 2003 17 711-716.
70. Vallette-Kasic S, Brue T, Pulichino AM, Gueydan M, Barlier A, David M, Nicolino M, Malpuech G, Dechelotte P, Deal C, Van VG, de VM, Riepe FG, Partsch CJ, Sippell WG, Berberoglu M, Atasay B, de ZF, Beckers D, Kyllo J, Donohoue P, Fassnacht M, Hahner S, Allolio B, Noordam C, Dunkel L, Hero M, Pigeon B, Weill J, Yigit S, Brauner R, Heinrich JJ, Cummings E, Riddell C, Enjalbert A & Drouin J. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. Journal of Clinical Endocrinology and Metabolism 2005 90 1323-1331.
71. Metherell LA, Savage MO, Dattani M, Walker J, Clayton PE, Farooqi IS & Clark AJ. TPIT mutations are associated with early-onset, but not late-onset isolated ACTH deficiency. European Journal of Endocrinology 2004 151 463-465.
72. Weintrob N, Drouin J, Vallette-Kasic S, Taub E, Marom D, Lebenthal Y, Klinger G, Bron-Harlev E & Shohat M. Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene. Pediatrics 2006 117 e322-e327.
73. Sornson MW, Wu W, Dasen IS, Flynn SE, Norman DJ, O'Connell SM, Gukovsky I, Carriere C, Ryan AK, Miller AP, Zuo L, Gleiberman AS, Andersen B, Beamer WG & Rosenfeld MG. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996 384 327-333.
74. Gage PJ, Roller ML, Saunders TL, Scarlett LM & Camper SA. Anterior pituitary cells defective in the cell-autonomous factor, df, undergo cell lineage specification but not expansion. Development 1996 122 151-160.
75. Tang K, Bartke A, Gardiner CS, Wagner TE & Yuri JS. Gonadotropin secretion, synthesis, and gene expression in human growth hormone transgenic mice and in Ames dwarf mice. Endocrinology 1993 132 2518-2524.
76. Wu W, Cogan JD, Pfaffle RW, Dasen JS, Frisch H, O'Connell SM, Flynn SE, Brown MR, Mullis PE, Parks JS, Phillips JA III & Rosenfeld MG. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nature Genetics 1998 18 147-149.
77. Deladoey J, Fluck C, Buyukgebiz A, Kuhlmann BV, Eble A, Hindmarsh PC, Wu W & Mullis PE. 'Hot spot' in the PROP1 gene responsible for combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1999 84 1645-1650.
78. Cogan JD, Wu W, Phillips JA, Arnhold IJ, Agapito A, Fofanova OV, Osorio MG, Bircan I, Moreno A & Mendonca BB. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 3346-3349.
79. Turton JPG, Mehta A, Raza J, Woods KS, Tiulpakov A, Cassar J, Chong K, Thomas PQ, Eunice M, Ammini AC, Bouloux PM, Starzyk J, Hindmarsh PC & Dattani MT. Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). Clinical Endocrinology 2005 63 10-18.
80. Duquesnoy P, Roy A, Dastot F, Ghali I, Teinturier C, Netchine I, Cacheux V, Hafez M, Salah N, Chaussain JL, Goossens M, Bougneres P & Amselem S. Human Prop-1: cloning, mapping, genomic structure. Mutations in familial combined pituitary hormone deficiency. FEBS Letters 1998 437 216-220.
81. Reynaud R, Chadli-Chaieb M, Vallette-Kasic S, Barlier A, Sarles J, Pellegrini-Bouflier I, Enjalbert A, Chaieb L & Brue T. A familial form of congenital hypopituitarism due to a PROP1 mutation in a large kindred: phenotypic and in vitro functional studies. Journal of Clinical Endocrinology and Metabolism 2004 89 5779-5786.
82. Osorio MG, Kopp P, Marui S, Latronico AC, Mendonca BB & Arnhold IJ. Combined pituitary hormone deficiency caused by a novel mutation of a highly conserved residue (F88S) in the homeodomain of PROP-1. Journal of Clinical Endocrinology and Metabolism 2000 85 2779-2785.
83. Lebl J, Vosahlo J, Pfaeffle RW, Stobbe H, Cerna J, Novotna D, Zapletalova J, Kalvachova B, Hana V, Weiss V & Blum WF. Auxological and endocrine phenotype in a population-based cohort of patients with PROP1 gene defects. European Journal of Endocrinology 2005 153 389-396.
84. Cogan JD, Wu W, Phillips JA III, Arnhold IJ, Agapito A, Fofanova OV, Osorio, MG, Bircan I, Moreno A & Mendonca BB. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 3346-3349.
85. Reynaud R, Barlier A, Vallette-Kasic S, Saveanu A, Guillet MP, Simonin G, Enjalbert A, Valensi P & Brue T. An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. Journal of Clinical Endocrinology and Metabolism 2005 90 4880-4887.
86. Arroyo A, Pernasetti F, Vasilyev VV, Amato P, Yen SS & Mellon PL. A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty. Clinical Endocrinology 2002 57 283-291.
87. Fluck C, Deladoey J, Rutishauser K, Eble A, Marti U, Wu W & Mullis PE. Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg-Cys at codon 120 (R120C). Journal of Clinical Endocrinology and Metabolism 1998 83 3727-3734.
88. Vallette-Kasic S, Barlier A, Teinturier C, Diaz A, Manavela M, Berthezene F, Bouchard P, Chaussain JL, Brauner R, Pellegrini-Bouiller I, Jaquet P, Enjalbert A & Brue T. PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. Journal of Clinical Endocrinology and Metabolism 2001 86 4529-4535.
89. Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS & Arnhold IJ. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301, G302 in the PROP1 gene. Journal of Clinical Endocrinology and Metabolism 1999 84 942-945.
90. Asteria C, Oliveira JH, Abucham J & Beck-Peccoz P. Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 gene. European Journal of Endocrinology 2000 143 347-352.
91. Pernasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, Lourenco DM & Mellon PL. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. Journal of Clinical Endocrinology and Metabolism 2000 85 390-397.
92. Riepe FG, Partsch CJ, Blankenstein O, Monig H, Pfaffle RW & Sippell WG. Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. Journal of Clinical Endocrinology and Metabolism 2001 86 4353-4357.
93. Bottner A, Keller E, Kratzsch J, Stobbe H, Weigel JF, Keller A, Hirsch W, Kiess W, Blum WF & Pfaffle RW. PROP1 mutations cause progressive deterioration of anterior pituitary function including adrenal insufficiency: a longitudin analysis. Journal of Clinical Endocrinology and Metabolism 2004 89 5256-5265.
94. Agarwal G, Bhatia V, Cook S & Thomas PQ. Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. Journal of Clinical Endocrinology and Metabolism 2000 85 4556-4561.
95. Fofanova O, Takamura N, Kinoshita E, Vorontsov A, Vladimirova V, Dedov I, Peterkova V & Yamashita S. MR imaging of the pituitary gland in children and young adults with congenital combined pituitary hormone deficiency associated with PROP1 mutations. American Journal of Roentgenoloy 2000 174 555-559.
96. Voutetakis A, Argyropoulou M, Sertedaki A, Livadas S, Xekouki P, Maniati-Christidi M, Bossis I, Thalassinos N, Patronas N & Dacou-Voutetakis C. Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. Journal Clinical Endocrinology and Metabolism 2004 89 2200-2406.
97. Parks JS, Brown MR, Baumbach L, Sanchez JC, Stanley CA, Gianella-Neto D, Wu W & Oyesiku N. Natural history and molecular mechanisms of hypopituitarism with large sella turcica. Presented at the American Endocrine Society Meeting. New Orleans, June 24-27, Abstract no. P3-409 p 470, 1998.
98. Cushman LJ, Watkins-Chow DE, Brinkmeier ML, Raetzman LT, Radak AL, Lloyd RV & Camper SA. Persistent Prop1 expression delays gonadotrope differentiation and enhances pituitary tumor susceptibility. Human Molecular Genetics 2001 10 1141-1153.
99. Bodner M, Castrillo JL, Theill LE, Deerinck T, Ellisman M & Karin M. The pituitary-specific transcription factor GHF-1 is a homeobox-containing protein. Cell 1988 55 505-518.
100. Andersen B & Rosenfeld MG. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocrine Reviews 2001 22 2-35.
101. Rhodes SJ, DiMattia GE & Rosenfeld MG. Transcriptional mechanisms in anterior pituitary cell differentiation. Current Opinion in Genetics and Development 1994 4 709-717.
102. Li S, Crenshaw EB III, Rawson EJ, Simmons DM, Swanson LW & Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990 347 528-533.
103. Andersen B & Rosenfeld MG. Pit-1 determines cell types during development of the anterior pituitary gland. A model for transcriptional regulation of cell phenotypes in mammalian organogenesis. Journal of Biological Chemistry 1994 269 29335-29338.
104. Rhodes SJ, Chen R, DiMattia GE, Scully KM, Kalla KA, Lin SC, Yu VC & Rosenfeld MG. A tissue-specific enhancer confers Pit-1-dependent morphogen inducibility and autoregulation on the pit-1 gene. Genes and Development 1993 7 913-932.
105. Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y & Kohno H. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nature Genetics 1992 1 56-58.
106. Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD & Radovick S. A 'hot spot' in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. Journal of Clinical Endocrinology and Metabolism 1995 80 679-684.
107. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD & Wondisford FE. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992 257 1115-1118.
108. Kishimoto M, Okimura Y, Fumoto M, Iguchi G, Iida K, Kaji H & Chihara K. The R271W mutant form of Pit-1 does not act as a dominant inhibitor of Pit-1 action to activate the promoters of GH and prolactin genes. European Journal of Endocrinology 2003 148 619-625.
109. Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, Van-der-Nat H, Van-den-Brande JL, Rosenfeld MG & Ingraham HA. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992 257 1118-1121.
110. Pfaffie RW, Martinez R, Kim C, Frisch H, Lebl J, Otten B & Heimann G. GH and TSH deficiency. Experimental and Clinical Endocrinology and Diabetes 1997 105 (Suppl 4) 1-5.
111. Turton JPG, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, Tiulpakov A, Zdravkovic V, Hamilton J, Attard-Montalto S, Parascandalo R, Vella C, Clayton PE, Shalet S, Barton J, Brue T & Dattani MT. Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. Journal of Clinical Endocrinology and Metabolism 2005 90 4762-4770.
112. Cohen LE & Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocrine Reviews 2002 23 431-442.
113. Carvalho LR, Woods KS, Mendonca BB, Marcal N, Zamparini AL, Stifani S, Brickman JM, Arnhold IJ & Dattani MT. A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. Journal of Clinical Investigation 2003 112 1192-1201.
114. Coya R, Vela A, Perez de Nanclares G, Rica I, Castano L, Busturia MA, Martul P & the GEDPIT group, Panhypopituitarism: genetic versus acquired etiological factors. Journal of Pediatric Endocrinology and Metabolism 2007 20 27-36.